Short answer
Rezolute, Inc. (RZLT) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). November 13, 2026 press release announces an interim update on Rezolute’s upLIFT study.
Rezolute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- November 13, 2026 press release announces an interim update on Rezolute’s upLIFT study
- Study update represents potentially material clinical-development information for Rezolute investors
- Investors should review the accompanying press release for interim efficacy, safety and program details
Item 8.01 · Other Events
- Item 8.01 incorporates most of the Item 7.01 press release into the filing
- Investor significance depends on the underlying announcement in the referenced press release
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 upLIFT primary endpoint achieved: 13 of 16 participants met the required 50% GIR reduction
- 12 responders completely discontinued IV glucose, strengthening ersodetug’s potential clinical benefit in tumor hyperinsulinism
- Preliminary result exceeds the statistical threshold of at least 9 responders, pending final confidence-interval analysis
- Final topline results and statistical analysis expected by mid-December 2026
- FDA discussions planned for Q1 2027, with potential BLA submissions for tumor and congenital HI in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Rezolute, Inc. 8-K filings
Get the next RZLT 8-K as it lands
Follow RZLT for push alerts, or ask the research agent what this filing means.